Diagnostyka (DIA) Q1 2026 earnings summary

Executive summary

• Revenue grew 13.4% year-over-year to PLN 670.9 million, driven by organic expansion, acquisitions, and higher average prices.

• Recurring EBITDA increased 11.4% year-over-year to PLN 179.6 million, with a margin of 26.8%.

• Net profit attributable to owners rose 13.3% year-over-year to PLN 82.6 million.

• Six acquisitions in laboratory diagnostics and two in diagnostic imaging were completed, expanding capabilities.

• Major investments included new laboratories in Gdynia and Gliwice and the launch of a new SAP ERP system.

Financial highlights

• Operating profit increased to PLN 123.1 million from PLN 112.2 million year-over-year.

• Diagnostic test volume reached 45.8 million, up 1.2% year-over-year.

• B2C revenue grew 9.2% and B2B revenue grew 8.2% year-over-year.

• Average selling price in diagnostic imaging rose 29.4% year-over-year due to sales mix changes.

• Earnings per share rose to PLN 2.45 from PLN 2.16 year-over-year.

Outlook and guidance

• Revenue expected to grow low/mid teens percent year-over-year in 2026.

• Average price per test to increase high single digits; test volume to grow low/mid single digits.

• Recurring EBITDA margin projected close to 2025 levels.

• Ongoing investments in automation, digitisation, and AI are expected to enhance operational efficiency.

• Wage pressure and competition for skilled personnel remain key challenges.